We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-21.25%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$791M
AUM Growth
+$150M
Cap. Flow
+$346M
Cap. Flow %
43.72%
Top 10 Hldgs %
55.59%
Holding
46
New
16
Increased
14
Reduced
9
Closed
6

Top Buys

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$44.2M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$42.8M
3
PBYI icon
Puma Biotechnology
PBYI
+$41.4M
4
ZGNX
Zogenix, Inc.
ZGNX
+$40.9M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$30.2M

Top Sells

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$36.8M
2
ECYT
Endocyte, Inc. Common Stock
ECYT
+$28.5M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$20M
4
VYGR icon
Voyager Therapeutics
VYGR
+$13.3M
5
ARGX icon
argenx
ARGX
+$9.82M

Sector Composition

Rank Sector Weight
1 Healthcare 86.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ENTA icon
26
Enanta Pharmaceuticals
ENTA
$366M
$10.2M 1.28%
143,481
-66,919
-32% -$5.13M
AMAG
27
DELISTED
AMAG Pharmaceuticals
AMAG
$10.1M 1.28%
+664,681
New +$12.7M
KA
28
DELISTED
Kineta, Inc. Common Stock
KA
$9.87M 1.25%
+21,753
New +$14.7M
YARW
29
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$9.08M 1.15%
612
+250
+69% +$5.6M
NVAX icon
30
CALL
Novavax
NVAX
$1.2B
$8.28M 1.05%
+225,000
New +$8.72M
PTGX icon
31
Protagonist Therapeutics
PTGX
$8.79B
$6.43M 0.81%
955,618
-26,831
-3% -$213K
ITCI
32
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$4.56M 0.58%
400,000
+200,000
+100% +$3.23M
VYGR icon
33
Voyager Therapeutics
VYGR
$183M
$3.43M 0.43%
365,132
-1,034,868
-74% -$13.3M
MDGL icon
34
Madrigal Pharmaceuticals
MDGL
$10.8B
$3.1M 0.39%
27,500
-12,900
-32% -$2M
ALNY icon
35
Alnylam Pharmaceuticals
ALNY
$27.5B
$2.93M 0.37%
40,197
-259,803
-87% -$20M
SAGE
36
CALL
DELISTED
Sage Therapeutics
SAGE
$2.49M 0.31%
+26,000
New +$2.98M
SAGE
37
PUT
DELISTED
Sage Therapeutics
SAGE
$2.49M 0.31%
+26,000
New +$2.98M
ARGX icon
38
argenx
ARGX
$53.4B
$1.78M 0.22%
18,500
-110,560
-86% -$9.82M
VIRX
39
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$132K 0.02%
9,085
-19,486
-68% -$795K
STRM
40
DELISTED
Streamline Health Solutions
STRM
$105K 0.01%
8,676
– –
EXEL icon
41
Exelixis
EXEL
$13.3B
– –
-2,075,000
Closed -$36.8M
ZYME icon
42
Zymeworks
ZYME
$1.61B
– –
-241,970
Closed -$3.8M
ACER
43
DELISTED
Acer Therapeutics Inc
ACER
– –
-58,461
Closed -$1.8M
SRRA
44
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-12,271
Closed -$834K
ECYT
45
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-1,606,100
Closed -$28.5M
CTIC
46
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-21,441
Closed -$46K
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2018 Portfolio in Review

As of Q4 2018, Great Point Partners held 46 positions worth $791M, up 23% from $642M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Great Point Partners deployed $346M of net new capital in Q4 2018, opening 16 new positions and adding to 14 existing holdings. Its largest new stake was Global Blood Therapeutics, Inc.: 1,180,000 shares worth $48.4M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 96% a quarter earlier.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $20M trimmed.

  • Great Point Partners's largest Q4 2018 buy was Global Blood Therapeutics, Inc.: 1,180,000 shares worth $48.4M.
  • Great Point Partners added most to Acadia Pharmaceuticals in Q4 2018, an estimated $30.2M increase.
  • Great Point Partners's biggest Q4 2018 reduction was Alnylam Pharmaceuticals, cutting an estimated $20M.
  • Great Point Partners fully exited Exelixis in Q4 2018, selling an estimated $36.8M.
  • Great Point Partners's ten largest holdings make up 56% of its $791M portfolio in Q4 2018.
  • Great Point Partners opened 16 new positions and closed 6 in Q4 2018.
  • Great Point Partners's portfolio value rose 23% quarter-over-quarter to $791M.

Based on Great Point Partners's 13F filing for Q4 2018, filed 15 Feb 2019.